[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-surgery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,77,123,146,172,199,229,260,286],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100597815","evaluation-of-virtual-reality-for-reducing-opioid-use-after-cardiac-and-thoracic-surgery-100597815",false,"NCT07063394","Evaluation of Virtual Reality for Reducing Opioid Use After Cardiac and Thoracic Surgery","Evaluation of the Efficacy of Virtual Reality as a Therapeutic Method to Reduce Opioid Consumption in Postoperative Cardiac and Thoracic Surgery","VR-USP","Inclusion Criteria:\n\n* Patients undergoing elective cardiac or thoracic surgeries at the Heart Institute (InCor) of the Hospital das Clínicas of the University of São Paulo.\n* Eligible thoracic surgeries include: pulmonary decortication, thoracic sympathectomy, video-assisted thoracoscopic surgery (VATS), pulmonary biopsy, and pectus excavatum repair using the Nuss procedure.\n* Patients aged between 16 and 40 years.\n* Preserved cognitive function, indicated by a Mini-Mental State Examination (MMSE) score of ≥ 25.\n\nExclusion Criteria:\n\n* Visual impairments.\n* Cognitive impairment (MMSE ≤ 24).\n* Severe upper limb motor limitations.\n* Claustrophobia.\n* Spatial disorientation.\n* Motion sickness or vestibular disorders.\n* Infectious or contagious diseases.","ALL","16 Years","40 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial aims to evaluate the efficacy of virtual reality (VR) as an adjunctive therapeutic method to reduce opioid consumption during the postoperative period of cardiac and thoracic surgeries. Conducted at InCor\u002FHCFMUSP, this single-center, prospective, randomized trial will include 60 patients aged 16 to 40 undergoing procedures such as valve replacements, pulmonary decortication, and video-assisted thoracic surgeries.\n\nPatients will be randomized into three groups. The Interactive VR group receives standard anesthesia protocol combined with interactive VR therapy using games and immersive environments. The Passive VR group receives standard protocol combined with passive 360-degree immersive videos. The Control group receives standard anesthesia protocol without VR intervention. The intervention occurs in three daily sessions lasting 30-45 minutes each over the first five postoperative days or until hospital discharge.\n\nThe primary objective is to measure the reduction in total opioid consumption through medical prescriptions and patient-controlled analgesia (PCA) pump usage. Secondary objectives include pain intensity assessed by the Visual Analogue Scale (VAS), incidence of postoperative nausea and vomiting (PONV), duration of mechanical and non-invasive ventilation, length of stay in the ICU and hospital, occurrence of paralytic ileus, patient satisfaction, and cognitive status using the Mini-Mental State Examination (MMSE).\n\nOpioids are standard for postoperative pain but are associated with adverse effects like respiratory depression. VR offers an innovative approach by creating immersive environments that serve as cognitive distractions to modulate pain perception and reduce anxiety. The study anticipates that VR will enhance pain control and improve recovery metrics, serving as a safe and scalable complement to traditional postoperative management.",[28,29,30,31,32],"Heart Surgery","Thoracic Surgery","Opioid","Virtual Reality","Pain",[34,29,30,31,32],"Heart surgery","RECRUITING","2026-04-10",{"date":38,"type":39},"2026-04-15","ACTUAL",{"date":41,"type":39},"2024-12-10",{"date":43,"type":22},"2027-12-30",{"name":45,"class":46},"Filomena R B G Galas","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100589199","efficacy-of-carbohydrate-loading-in-diabetic-type-2-patients-undergoing-cabg-surgery-on-cpb-100589199","NCT06951308","Efficacy of Carbohydrate Loading in Diabetic Type 2 Patients Undergoing CABG Surgery on CPB","CLDM-CABG","Inclusion Criteria:\n\nAll diabetic type 2 patients undergoing isolated on-pump coronary artery bypass surgery.\n\nExclusion Criteria:\n\n* Missing data.\n* Patients outside the study period.\n* Patients undergoing other cardiac surgeries.\n* Patients diagnosed with type 1 diabetes mellitus.",{"count":56,"type":22},50,[25],"Enhanced recovery after surgery protocols aim to optimize perioperative care and improve surgical outcomes. Preoperative carbohydrate loading has demonstrated benefits in reducing insulin resistance and improving patient outcomes. While non-diabetic patients benefit from this approach, its efficacy in diabetic type 2 patients undergoing CABG remains less understood. This study aims to address this gab by evaluating the physiological and clinical outcomes for carbohydrate loading in this specific population.",[28,60],"Ischemic Heart Disease",[62,63,64,65,66],"Enhanced recovery program","carbohydrate loading","coronary artery bypass grafting","heart surgery","postoperative recovery","2026-03-17",{"date":69,"type":39},"2026-03-19",{"date":71,"type":39},"2025-04-01",{"date":73,"type":22},"2026-12-31",{"name":75,"class":76},"Damascus University","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":98,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":47},"100620224","safety-and-performance-evaluation-of-cpb-venous-and-arterial-cannulas-100620224","NCT07354841","Safety and Performance Evaluation of CPB Venous and Arterial Cannulas","A Two Phases Clinical Investigation Consisting of a Pre-Market, Pilot, Interventional, Not Randomized, Monocentric Investigation to Evaluate the Safety of PVC Arterial Cannula and PVC Venous Cannula (Class III Medical Devices) Intended to be Used During Cardiopulmonary Bypass (CPB) Procedure Followed by a Pre-Market, Pivotal, Interventional, Randomized, Non- Inferiority, Monocentric Investigation to Confirm the Safety and Evaluate the Performance of the Same Cannulas","Inclusion Criteria:\n\n1. Patient is considered able and willing to provide written informed consent according to the ethically approved informed consent form;\n2. Female and male patients aged ≥ 18;\n3. Body weight between 60 and 120 kg;\n4. Body surface area (BSA) between 1.5 and 2.5 m2;\n5. Patients scheduled to undergo central cannulation for cardiopulmonary bypass (CPB) in elective surgery procedures (isolated coronary and\u002For aortic valve surgery).\n\nExclusion Criteria:\n\n1. Emergency cases;\n2. Re-do cardiac surgery procedure;\n3. Diabetes mellitus;\n4. Hematologic diseases or history of thrombophilia;\n5. Pregnancy or breastfeeding;\n6. Concomitant major cardiac procedures;\n7. Active malignant\u002Fmetastatic neoplasm of any type;\n8. Presence of pneumothorax and\u002For pulmonary emphysema;\n9. Significant central nervous system injury;\n10. Current intracranial hemorrhage;\n11. Immunosuppression;\n12. Contraindication for therapeutic anticoagulation (e.g., heparin);\n13. Anatomical and structural abnormalities which, in the opinion of the Investigator, may interfere with the participation to the study;\n14. Abnormal or pathological cannulation site;\n15. Uncontrolled active bleeding;\n16. Awaiting transplantation;\n17. Requiring preoperative extracorporeal membrane oxygenation;\n18. Presence of any relevant severe condition or clinically relevant abnormal laboratory parameters that in the opinion of the Investigator may interfere with the participation to the study.\n19. Patient is taking part in another interventional clinical study;\n20. Patient is not able to understand the nature of this study or is unwilling or unable to attend the EOS Visit.","18 Years",{"count":86,"type":22},80,[25],"This is a two-phase study evaluating the Eurosets arterial and venous cannulas for use during cardiopulmonary bypass (CPB) procedures. Phase 1 is a pilot study focused on assessing cannula safety. Phase 2 is a pivotal study aimed at confirming safety and evaluating efficacy through comparison with Medtronic cannulas (control group).\n\nThe results will be compared for non-inferiority with those obtained using the control group cannulas.",[90,28,91,92,93,94,95,96,97],"Cardiac Surgery","Cardiopulmonary Bypass","Coronary Surgery","Aortic Valve Surgery","Cannulation","Venous Cannulation","Arterial Cannulation","Coronary Surgery With Cardiopulmonary Bypass",[99,100,101,91,90,102,103,104,93,92,105,106,107,108,109,110,111,112],"Arterial Cannula","Venous Cannula","Extracorporeal Circulation","Medical Device","Device Safety","Device Performance","Two Phases clinical investigation","Monocentric Study","Two Phases Study","Serious Adverse Events (SAE)","CVP","NIRS","Venous Cannula Drainage Pressure","Arterial Cannula Reinfusion Pressure","2026-01-12",{"date":115,"type":39},"2026-01-21",{"date":117,"type":39},"2025-10-21",{"date":119,"type":22},"2026-09-30",{"name":121,"class":122},"Eurosets S.r.l.","INDUSTRY",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":144,"locationsCount":47},"100571530","modeling-blood-management-and-hemolytic-risk-in-pediatric-heart-surgery-100571530","NCT06721455","Modeling Blood Management and Hemolytic Risk in Pediatric Heart Surgery","Mathematical Modeling of Salvaged Red Blood Cells-based Blood Management Strategy and Their Hemolytic Risk in Pediatric Cardiac Surgery","Inclusion Criteria:\n\n* pediatric patients under 18 years of age undergoing cardiac surgery with clear prime on cardio-pulmonary bypass (CPB) at Boston Children's Hospital (BCH).\n\nExclusion Criteria:\n\n* patients with known hemolytic disorders, patients on nitric oxide preoperatively, and patients found to have abnormal coagulation on routine preoperative assessment. Patients receiving heparin, American Society of Anesthesia (ASA) status, apixaban, warfarin, or bivalirudin held appropriately (i.e. for elective surgery) will not be excluded","0 Years","17 Years",{"count":56,"type":22},"OBSERVATIONAL","This study aims to learn more about blood management in children undergoing heart surgery, such as the right amounts, and the best blood products, to administer. It also aims to develop a mathematical model that may help researchers better predict and treat patients who need blood transfusions during heart surgery.",[28,136,137],"Blood Transfusion","Hemolysis","2026-01-05",{"date":140,"type":39},"2026-01-07",{"date":142,"type":39},"2025-08-01",{"date":73,"type":22},{"name":145,"class":76},"Boston Children's Hospital",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":47},"100590488","comparison-of-ultrasound-guided-serratus-combination-plane-blocks-and-local-wound-infiltration-for-postoperative-analgesia-management-in-minimally-invasive-cardiac-surgery-mics-100590488","NCT06968065","Comparison of Ultrasound-Guided Serratus Combination Plane Blocks and Local Wound Infiltration for Postoperative Analgesia Management in Minimally Invasive Cardiac Surgery (MICS)","Inclusion Criteria:\n\n* Age 18-75 years\n* Undergoing MICS with left-sided 4th-5th intercostal incision\n* ASA I-III\n* Informed consent provided\n\nExclusion Criteria:\n\n* Coagulopathy or on anticoagulants\n\n  * Allergy to local anesthetics or opioids\n  * Local infection at block site\n  * Pregnancy or lactation\n  * Bilateral thoracic incisions\n  * Refusal to participate","75 Years",{"count":21,"type":22},[25],"This randomized, prospective, single-blinded study aims to compare the efficacy of ultrasound-guided serratus anterior plane (SAP) block combined with serratus-intercostal interfascial plane (SIP) block versus local wound infiltration (LWI) for postoperative analgesia in patients undergoing minimally invasive cardiac surgery (MICS). The primary outcome is total perioperative and postoperative opioid consumption. Secondary outcomes include postoperative pain scores (NRS), opioid-related side effects, block-related complications, and ICU stay duration.",[157,28,158],"Pain, Postoperative","Analgesia",[157,160,158,161,162],"Heart Surgery, Minimally Invasive","Bupivacaine","Opioid-Related Disorders","2025-05-05",{"date":165,"type":39},"2025-05-13",{"date":167,"type":39},"2024-10-17",{"date":169,"type":22},"2025-06",{"name":171,"class":76},"İstanbul Yeni Yüzyıl Üniversitesi",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":47},"100563081","positive-pressure-therapy-to-optimize-lung-function-after-heart-surgery-100563081","NCT06611527","Positive Pressure Therapy to Optimize LUNG Function After Heart Surgery","Comparison Between Two Methods of Positive Pressure Therapy in the Prevention of Pulmonary Complications in the Immediate Postoperative Period of Cardiac Surgery: a Prospective, Randomized Clinical Trial","PRO-LUNGHS","Inclusion Criteria:\n\n* Immediate postoperative period of myocardial revascularization and\u002For valve replacement or plastic surgery;\n* Patients in the preoperative period at risk of developing pulmonary complications, characterized by the presence of at least 2 of the following risk factors: age ≥ 70 years, productive cough, diabetes, history of smoking, chronic obstructive pulmonary disease (COPD) defined by forced expiratory volume in 1 second (FEV1) lower than 75% of predicted, body mass index (BMI) ≥ 27 kg\u002Fm2, or only FEV1 lower than 80% and FEV1\u002Fforced vital capacity (FVC) ratio lower than 70% of predicted; OR patients in the postoperative period (up to 12 hours after extubation) with mild to moderate complications characterized by a pulmonary complication score lower than 3.\n\nExclusion Criteria:\n\n* Hemodynamic instability characterized by mean arterial pressure (MAP) lower than 60mmHg and\u002For acute arrhythmia of any etiology;\n* Need for intra-aortic balloon;\n* Duration of invasive mechanical ventilation exceeding 24 hours after surgery;\n* Pulmonary complication score ≥ grade 3;\n* Presence of signs of acute respiratory failure, such as respiratory rate (f) ≥ 25 breaths\u002Fmin and use of accessory muscles;\n* Chest tube with air leak;\n* Use of a pacemaker or implantable or external cardioverter-defibrillator.",{"count":181,"type":22},156,[25],"The most common cardiac surgeries are myocardial revascularization and valve replacement or plastic surgery. In the postoperative period of cardiac surgeries, the incidence of pulmonary complications ranges from 30% to 50% and is associated with increased length of hospital stay and morbidity and mortality. To reduce or minimize the occurrence of these complications, respiratory physiotherapy employs positive pressure reexpansion therapies, such as continuous positive airway pressure (CPAP) and positive pressure support with positive end-expiratory pressure (PS+PEEP).\n\nThe goal of this clinical trial is to compare the effects of two positive pressure therapies, CPAP versus PS+PEEP, on the incidence of pulmonary complications in patients in the postoperative period of myocardial revascularization and valve replacement or plastic surgery, with mild to moderate pulmonary dysfunction.\n\nThe main question it aims to answer is: Do patients in the immediate postoperative period of myocardial revascularization or valve replacement\u002Fplastic surgery, exhibiting mild to moderate pulmonary dysfunction, experience a comparable reversal of pulmonary conditions when treated with PS+PEEP versus CPAP?\n\nParticipants will undergo the following assessments: spirometry, respiratory muscle strength testing, handgrip strength testing, and electrical impedance tomography.\n\nIn the immediate postoperative period, participants will be randomized into two treatment groups: • Control Group PS+PEEP - application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml\u002Fkg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%; • Experimental Group CPAP - application of CPAP at 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.",[185,186,187,188,189,28],"Postoperative Period","Physical Therapy Modalities","Continuous Positive Airway Pressure","Respiratory Function Tests","Pulmonary Atelectasis","2025-04-08",{"date":192,"type":39},"2025-04-10",{"date":194,"type":39},"2025-01-08",{"date":196,"type":22},"2027-12",{"name":198,"class":76},"Federal University of São Paulo",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":28,"eligibilityCriteria":205,"healthyVolunteers":206,"sex":17,"minAge":84,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":219,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100579941","mandala-coloring-and-its-effect-on-anxiety-and-depression-before-open-heart-surgery-100579941","NCT06830837","Mandala Coloring and Its Effect on Anxiety and Depression Before Open Heart Surgery","The Effect of Mandala Coloring on Anxiety and Depression Before Open Heart Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Having no history of previous cardiothoracic surgery, eing newly diagnosed with CAD and registered on a wait list for CABG surgery, having literacy in the Turkish language\n\nExclusion Criteria:\n\n* having a history of cognitive impairment, having other life-threatening medical conditions, such as cancer or stroke",true,"65 Years",{"count":209,"type":22},84,[25],"This study was conducted to determine the Effect of Mandala Coloring on Anxiety and Depression Before Open Heart Surgery. This was a randomized, controlled experimental study. The sample comprised 84 patients who underwent open heart surgery (control: 41; experimental: 43).\n\nEight pre-selected mandala drawings will be printed on separate A4 (21.0 cm × 29.7 cm) papers. After the patients are admitted to the hospital for the surgery process, the patients in the experimental group will be provided with at least 2 hours of mandala coloring per day until the day of their surgery. No intervention will be applied to the control group patients.",[28,213,214],"Mandala Painting","Anxiety",[65,216,217,218],"anxiety","mandala coloring","Depression","NOT_YET_RECRUITING","2025-02-12",{"date":222,"type":39},"2025-02-17",{"date":224,"type":22},"2025-03-20",{"date":226,"type":22},"2025-12-20",{"name":228,"class":76},"Ataturk University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":47},"100533211","anticoagulation-and-inflammation-monitoring-in-patients-after-heart-and-vascular-interventions-100533211","NCT06222866","Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions","Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions: Prospective Observational Study","PAC-AIM","Inclusion Criteria:\n\n* Age: \\> 17 years\n* Informed written consent\n* Scheduled for cardiac intervention where the use of UFH is expected (elective surgery)\n* Scheduled for vascular intervention when the need for perioperative anticoagulation is expected (elective surgery)\n* Patients receiving ECMO support\n\nExclusion Criteria:\n\n* Patients that are known to be pregnant\n* Known participation in other interventional clinical trial",{"count":238,"type":22},400,"The goal of this prospective observational study is to evaluate the most appropriate anticoagulation monitoring tool for unfractionated heparin (UFH), by comparison of different monitoring modalities in relation to adverse events occurrence (thrombosis\u002Fbleeding).\n\nThe main study questions are:\n\n* What is the most appropriate anticoagulation monitoring tool (ACT, aPTT, viscoelastic tests (ROTEM), and anti-Xa) for UFH\n* What is the incidence of adverse events associated with anticoagulation and inflammation after heart and vascular interventions\n* Is there an association of available anticoagulation thresholds and monitoring tests with bleeding and\u002For thrombosis occurrence\n* Is there an association of inflammation with delirium\n\nSecondary study objectives include:\n\n* Association of anticoagulation levels as measured by ACT, aPTT, viscoelastic tests (ROTEM), and anti-factor-Xa with adverse events\n* Correlation of each anticoagulation monitoring test with the UFH anti-Xa measurement\n* Correlation of each anticoagulation monitoring test with another (ACT, aPTT, ROTEM, anti-F-Xa) and the amount of blood loss post surgery\n* The incidence of UFH-rebound effect and the need for protamine application\n* Association of inflammation and increased \u002F reduced need for anticoagulation titration\n* Correlation of anticoagulation dosing with anticoagulation monitoring tests and adverse events\n* The association of inflammation with adverse events\n* The association and impact of inflammation on measured levels of anticoagulation with available tests\n* Influence of anticoagulation on mortality\n* Incidence of ECMO support\n* Incidence of delirium (hypoactive and hyperactive) and correlation with vital (newly onset postoperative atrial fibrillation amongst others) and laboratory parameters, including, and pre-existing neurological disorders",[28,241,242,243],"Vascular Surgery","Delirium","Hyperinflammatory Syndrome",[245,246,247,248,249,242,250],"cardiac surgery","vascular surgery","Anticoagulation","Adverse Events","Monitoring","Inflammation","2024-11-25",{"date":253,"type":39},"2024-11-26",{"date":255,"type":39},"2024-06-25",{"date":257,"type":22},"2026-12-01",{"name":259,"class":76},"Medical University Innsbruck",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":47},"100475419","study-of-the-relationship-between-the-oxygenation-state-and-lung-ultrasound-score-in-cardiac-surgery-100475419","NCT05470686","Study of the Relationship Between the Oxygenation State and Lung Ultrasound Score in Cardiac Surgery","Study of the Relationship Between the Relative Variation of PaO2\u002FFiO2 and the Variation of Lung Ultrasound Score During the First Session of Physiotherapy Associated With Non-invasive Ventilation in Cardiac Surgery Patients by Cardiopulmonary Bypass","PaFiKinESAP","Inclusion Criteria:\n\n* Person having received complete information on the organization of the research and having given written consent to participate\n* Person having benefited from a heart surgery under cardio-pulmonary bypass\n* Medical prescriptions for non invasive ventilation and physiotherapist\n* Age ≥ 18 years\n* 18.5 ≤ BMI ≤ 35 kg\u002Fm2\n* Visual Analogy Scale pain \\\u003C 4\n* Patient conscious and oriented: Glasgow 15\u002F15\n\nExclusion Criteria:\n\n* At the patient's request : a patient may withdraw from the research at any time without affecting the quality of care to which he or she is entitled (withdrawal of consent).\n* Cardiorespiratory arrest during the inclusion visit.\n* Need for orotracheal reintubation during the inclusion visit.\n* Patient non-cooperation during the inclusion visit.\n* Failure of the ultrasound machine during the inclusion visit.\n* Failure of the blood gas analyzer.\n* Glasgow \\\u003C 15 during the inclusion visit\n* PEEP \\> 6 cmH2O required during physiotherapy + non invasive ventilation session\n* PEEP \\\u003C 6 cmH2O required during physiotherapy + non invasive ventilation session\n* Premature interruption of the physiotherapy session + non invasive ventilation not hemodynamically tolerated\n* Need for a session of non invasive ventilation + physiotherapy \\> 30 minutes.",{"count":86,"type":22},[25],"After conventional cardiac surgery, many respiratory complications are possible. Therefore, the resuscitator prescribe physiotherapy and non invasive ventilation. The physiotherapist has few reliable tools to evaluate and follow the patient on his ventilatory function. Currently, lung ultrasound is little used in physiotherapy and no study explains the link between the lung ultrasound results and oxygenation patient state. Before considering the interest of lung ultrasound score as a criterion of effectiveness of a physiotherapy treatment through future studies, it is first important to objectivize the existence of a relationship between lung ultrasound score and the PaO2\u002FFiO2 ratio after cardiac surgery. Lung ultrasound could provide direct clinical information without having to resort to other more invasive examinations to objectify the improvement of the patient's oxygenation.\n\nMain objective To show that the relative change in the PaO2\u002FFiO2 ratio correlates with the change in lung ultrasound score measured in the short term between the beginning and the end of the first physiotherapy session associated with non invasive ventilation the day after surgery in cardiac patients\n\nSecondary objectives\n\n* To study the inter-operator (2 readers) reproducibility of the lung ultrasound score measurement.\n* To study the relationship between the relative variation of the PaO2\u002FFiO2 ratio and the variation of each of the 12 zones of the lung ultrasound score\n* To Study the relationship between the initial lung ultrasound score and the relative variation of the PaO2\u002FFiO2 ratio\n* To study the relative variation of the PaCO2 and the variation of the lung ultrasound score between the beginning and the end of the first session of physiotherapy management associated with NIV\n* To obtain from the patient in the short term feedback on his or her understanding of the explanations about lung ultrasound score provided by the physiotherapist during the session",[28],[65,273,274,275,276],"Lung ultrasound score","PaO2\u002FFiO2 ration","physiotherapy","Non invasive ventilation","2024-08-20",{"date":279,"type":39},"2024-08-21",{"date":281,"type":39},"2023-06-21",{"date":283,"type":22},"2025-07",{"name":285,"class":76},"Central Hospital, Nancy, France",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":47},"100516206","the-effect-of-virtual-reality-on-postoperative-pain-and-anxiety-in-cardiac-surgery-100516206","NCT06001502","The Effect of Virtual Reality on Postoperative Pain and Anxiety in Cardiac Surgery.","VRECOVERY","Inclusion Criteria:\n\n* Age ≥18 years or older with written informed consent\n* Patients undergoing surgical CABG\n\nExclusion Criteria:\n\n* Major comorbidities besides coronary artery disease\n* Complicated surgical procedure\n* Hearing and\u002For visual impairments\n* Psychiatric impairments\n* Complaints of vomiting and nausea\n* History of epilepsy\n* Claustrophobia\n* Facial wounds and skin defects at site of application\n* Patients placed in clinical isolation\n* Readmission to the intensive care unit",{"count":294,"type":22},100,[25],"The objective of this study is to investigate the effect of VR on post-operative pain and anxiety management in cardiac surgery patients undergoing a coronary artery bypass grafting (CABG) procedure.\n\nParticipants in the intervention group will receive a 20 minute session with the head mounted VR device on post-operative days 1,2 and 3.\n\nParticipants in the control group will be treated with conventional post-operative care.",[298,299,28,300,31],"Post Operative Pain","Post Operative Anxiety","Coronary Artery Bypass Grafting","2024-07-09",{"date":303,"type":39},"2024-07-10",{"date":305,"type":39},"2023-01-01",{"date":307,"type":22},"2024-09-01",{"name":309,"class":76},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]